| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
At the first step, we developed humanized mice by using NOJ (NOD/SCID/JAK3 KO) mouse. After CD34 positive hematopoietic stem cells were transplanted into a neonatal liver of NOJ mice, in the course of 10 weeks 30-70% human CD45 cells had been revealed. At the point of 16 weeks, enough amount of CD4 positive T cells existed. For the HTLV-1 infection, MMC treated MT-2 cells (2.5x106) were inoculated into the humanized mouse peritoneum. HTLV-1 infected T cells were increased in the mouse liver, spleen, bone marrow. These data suggested that there might be a ATL stem cell niche in the spleen. Moreover we analyzed the efficacy of new drug candidate of anti-HTLV-1 infection by using with this mouse model. This drug led to the suppression of proviral road of HTLV-1 in the peripheral blood and of infected T cell growth in the mouse model. These data suggested that the mouse model would be an effective tool for the new drug candidate.
|
